lexcorp
Revenue for the infusion system is estimated to be $4Mp.a in Brazil and up to $8Mp.a in Taiwan (after ramp up periods).
As an example of per hospital revenues, the Concord Hospital sales contract was estimated at $500k but retooling and developing the device to be a full infusion system delayed sales - the infusion system being the autostart fitted with the autoflush feature
The devices sell in hospitals for anywhere from $6 - $12+ each. I believe ALT gets between $1-2 royalty per unit. Can start to see the potential volumes if you factor in a new burette everyday per patient per bed who is hooked up to a pump.
Burette market is estimated to be $3Bn p.a but largely dominated by a few major multinationals - hence why they are securing the area less dominated (Taiwan & Brazil) first. Kind of like monopoly.
- Forums
- ASX - By Stock
- ALT
- Ann: Investor Presentation
Ann: Investor Presentation , page-15
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ALT (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
AHK
ARK MINES LIMITED
Ben Emery, Executive Director
Ben Emery
Executive Director
SPONSORED BY The Market Online